causal
Analysis v1
54
Pro
0
Against

Taking this supplement for 12 weeks doesn’t make people lose body fat or burn more calories at rest — even though it changes how their muscles use fuel.

Scientific Claim

Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol does not alter whole-body fat mass or energy expenditure in overweight and obese adults.

Original Statement

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

probability

Can suggest probability/likelihood

Assessment Explanation

RCT design supports causal inference for these outcomes. 'Not affected' and 'not altered' are accurate, but probability language is preferred due to small sample size and abstract-only access.

More Accurate Statement

Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol likely has no effect on whole-body fat mass or energy expenditure in overweight and obese adults.

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Systematic Review & Meta-Analysis
Level 1a

Whether EGCG+RES consistently fails to reduce fat mass or increase energy expenditure across populations and dosages.

What This Would Prove

Whether EGCG+RES consistently fails to reduce fat mass or increase energy expenditure across populations and dosages.

Ideal Study Design

A meta-analysis of ≥7 RCTs (n≥120 per trial) in overweight/obese adults comparing EGCG+RES (282+80 mg/d) vs placebo for ≥8 weeks, with primary outcomes: total fat mass (DXA) and 24-h energy expenditure (indirect calorimetry).

Limitation: Cannot determine if effects vary by sex, age, or baseline metabolic health.

Randomized Controlled Trial
Level 1b
In Evidence

Causal effect of EGCG+RES on fat mass and energy expenditure.

What This Would Prove

Causal effect of EGCG+RES on fat mass and energy expenditure.

Ideal Study Design

A double-blind RCT with 180 overweight/obese adults (BMI 27–35, aged 30–60) randomized to EGCG+RES or placebo for 12 weeks, with primary endpoints: total fat mass via DXA and 24-h energy expenditure via whole-room indirect calorimetry under controlled diet and activity.

Limitation: Does not assess long-term weight maintenance or body composition changes beyond 12 weeks.

Prospective Cohort Study
Level 2b

Whether lack of fat mass reduction with EGCG+RES predicts failure to maintain weight loss in obese individuals.

What This Would Prove

Whether lack of fat mass reduction with EGCG+RES predicts failure to maintain weight loss in obese individuals.

Ideal Study Design

A 2-year prospective cohort of 300 obese adults taking EGCG+RES (282+80 mg/d) or not, with quarterly DXA scans and energy expenditure measurements, adjusting for diet, exercise, and weight loss attempts.

Limitation: Cannot prove causation due to confounding by adherence and lifestyle.

Animal Model Study
Level 4

Why EGCG+RES enhances fat oxidation without reducing total fat mass (e.g., increased fat turnover without net loss).

What This Would Prove

Why EGCG+RES enhances fat oxidation without reducing total fat mass (e.g., increased fat turnover without net loss).

Ideal Study Design

A study in high-fat diet-fed mice (n=40/group) treated with EGCG+RES (equivalent human dose) for 12 weeks, measuring fat mass (MRI), fat oxidation rate (indirect calorimetry), lipolysis (glycerol release), and fat synthesis (de novo lipogenesis).

Limitation: Mouse fat metabolism and energy balance differ from humans.

Evidence from Studies

Supporting (1)

54

This study gave people the same supplements mentioned in the claim for 12 weeks and found their total body fat and how many calories they burned didn’t change — which is exactly what the claim says.

Contradicting (0)

0
No contradicting evidence found